A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors

Project Information

SenseGuard

Grant agreement ID: 946598

DOI

10.3030/946598

Project closed

EC signature date 26 March 2020

Start date 1 April 2020

End date 31 March 2023

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 3 567 185,00

EU contribution

€ 2 497 029,50

Coordinated by

NanoVation-GS
Israel

Periodic Reporting for period 2 - SenseGuard (A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors)

Reporting period: 2021-04-01 to 2023-03-31

Summary of the context and overall objectives of the project

Disease monitoring is key for patients with chronic respiratory conditions. Chronic Obstructive Pulmonary Diseases (COPD) is a long-term condition that causes inflammation in the lungs, making breathing difficult. It is a large growing public health problem, expected to become the third leading causes of death by 2030. Nevertheless, COPD patients lack of a frequent and accurate monitoring throughout their disease. This can result in non-adequate therapeutic measures, which can often lead to potential serious effects on patient’s status and high costs for healthcare systems.
To address this massive, worldwide problem, NanoVation’s goal – during the EIC Accelerator project - is to market a clinically validated SenseGuard™. SenseGuard™ is a breakthrough solution, for reliably monitoring of patients with respiratory diseases, including COPD, leveraging a unique nanosensor-based technology. It is an innovative wireless wearable device that enables continuous and non-invasive monitoring of lung functions derived from patients' tidal (normal) breathing.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

NanoVation has finalised the new generation design and developed the hardware and software for optimum performance. The company has also increased its production capacity, meeting its daily production target. NanoVation has commenced the validation activities (including patient recruitment for the clinical trials) and will continue to focus on it in the upcoming months.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Chronic respiratory diseases such as COPD, receive little attention and funding in comparison with other major causes of global morbidity and mortality. Accurate, constant monitoring of COPD patients is crucial to manage exacerbation and minimise outcome severity and costly intervention. Once commercialised, SenseGuard™ will contribute to effective management, therapies and treatment, which will also lead to decreased healthcare costs. By remotely monitoring COPD patients at home, SenseGuard™ will help to reduce admissions in hospitals and thus associated costs for healthcare facilities, thanks to early detection and timely intervention.

nv-logo-new.png